- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Crawford on Managing Febrile Neutropenia
July 2nd 2012, 9:11am
Multinational Association of Supportive Care in Cancer International Symposium
Jeffrey Crawford, MD, from Duke University Medical Center, on Managing Febrile Neutropenia.
Photos From the 2012 MASCC/ISOO Symposium
July 2nd 2012, 8:51am
Multinational Association of Supportive Care in Cancer International Symposium
A compilation of photos from the 2012 combined conferences of the Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO).
Dr. Holland on the Stigma Toward Psychosocial Care
June 30th 2012, 2:34pm
Multinational Association of Supportive Care in Cancer International Symposium
Dr. Jimmie Holland, from Memorial Sloan-Kettering Cancer Center, on the Stigma Toward Psychosocial Care.
Diarrhea Less Severe With Molecularly Targeted Agents Than With Standard Chemotherapy
June 30th 2012, 7:09am
Multinational Association of Supportive Care in Cancer International Symposium
Recent evidence shows that some of the newer molecularly targeted therapies can cause diarrhea, which can lead to dose reductions and alterations.
Targeted Therapies Safer for Heart Than Anthracyclines
June 30th 2012, 6:42am
Multinational Association of Supportive Care in Cancer International Symposium
Although molecularly targeted agents can cause cardiac damage, it appears to be reversible and related to cellular dysfunction, as distinct from agents such as anthracyclines that cause cellular death and irreversible cardiac dysfunction.
Dr. Gralla on Chemotherapy-Induced Nausea and Vomiting
June 30th 2012, 6:17am
Multinational Association of Supportive Care in Cancer International Symposium
Dr. Richard Gralla, from the Quality of Life Research Associates, on Chemotherapy-Induced Nausea and Vomiting.
Dr. Foley Discusses Guidelines for Cancer Pain Management
June 29th 2012, 7:42am
Multinational Association of Supportive Care in Cancer International Symposium
Dr. Kathleen Foley, from Memorial Sloan-Kettering Cancer Center, Discusses the World Health Organization Guidelines for Cancer Pain Management.
Dr. Grunberg Describes the MASCC International Symposium
June 29th 2012, 7:29am
Multinational Association of Supportive Care in Cancer International Symposium
Dr. Steven Grunberg, from the Vermont Cancer Center, Describes the 2012 Multinational Association of Supportive Care in Cancer Symposium.
Despite Progress, Complete Control of Chemotherapy-Induced Nausea Lags Behind Vomiting Control
June 29th 2012, 6:31am
Multinational Association of Supportive Care in Cancer International Symposium
Control of chemotherapy-induced nausea and vomiting (CINV) has come a long way in the past 30 years. Thirty years ago, about 10% of patients had complete control of emesis; in the 1990s about 50% had complete control. Today about 85% of patients treated with highly emetogenic chemotherapy have complete control of emesis.
Three Decades of Progress in Treating Febrile Neutropenia
June 29th 2012, 6:06am
Multinational Association of Supportive Care in Cancer International Symposium
Treatment of febrile neutropenia (FN) has dramatically improved over the past 3 decades, but there is room for improvement, according to Jean Klastersky, MD, Institut Jules Bordet, Brussels, Belgium.
ASCO President Recaps Top Stories From Meeting
June 6th 2012, 12:12pm
Dr. Michael P. Link, ASCO President, from Stanford University School of Medicine, on the top stories from the 2012 ASCO Annual Meeting.
2012 ASCO Annual Meeting Slideshow
June 6th 2012, 8:37am
Photos taken at the 2012 ASCO Annual Meeting held at the McCormick Place in Chicago, Illinois, from June 1-5, 2012.
Dr. Wood on Family Histories and Genetic Counseling
June 5th 2012, 1:58pm
Dr. Marie Wood, from the University of Vermont, on Family Histories and Genetic Counseling for Breast and Colorectal Cancers.
Two Newer Breast Cancer Therapies Not Superior to Standard Paclitaxel, Study Suggests
June 5th 2012, 6:52am
The newer and more expensive breast cancer treatments nab-paclitaxel and ixabepilone, failed to demonstrate superior efficacy versus standard care with weekly paclitaxel.
Study Finds Cymbalta Reduces Peripheral Neuropathy Pain
June 5th 2012, 6:44am
The antidepressant duloxetine relieved pain associated with chemotherapy-induced peripheral neuropathy for 59% of patients.
Pilot Study Evaluates a Proposed Quality Measure for Family History Collection and Genetic Testing Referral
June 5th 2012, 6:18am
Only half of those with breast cancer and one-quarter of those with colon cancer were referred for genetic counseling or testing by their physicians.
FDA and Industry Collaborating to Prevent Cancer Drug Shortages
June 5th 2012, 6:03am
Drug manufacturers are working with the FDA to report anticipated shortages earlier and ensure alternative sources of needed drugs are available.
Dr. Rugo on Paclitaxel Superiority in Advanced Breast Cancer
June 5th 2012, 6:01am
Dr. Hope Rugo, from the UCSK Comprehensive Cancer Center, on the First-line Superiority of Paclitaxel for Advanced Breast Cancer.
Two New BRAF-Targeted Therapies Reduce Disease Progression in Advanced Melanoma Patients
June 4th 2012, 4:31pm
Trametinib and dabrafenib delayed disease progression and showed a trend toward improved survival in patients with advanced melanoma.
Dr. Robert on the Trametinib METRIC Trial Results
June 4th 2012, 2:17pm
Dr. Caroline Robert, from the Institute Gustave Roussy in Paris, France, Discusses the MEK Inhibitor, Trametinib, METRIC Trial Results.